LAUSR

Background: Patients with advanced EGFR-mutated NSCLC benefit from treatment with EGFR TKIs. However, gaps in oncologists9 performance hamper their ability to integrate individualized treatments into the care of patients with this disease. This study was conducted to determine if an online, virtual patient simulation (VPS)-based continuing medical education (CME) intervention improved performance of oncologists in using appropriate strategies to diagnose and manage patients with advanced EGFR-mutated NSCLC. Methods: The CME intervention consisted of two cases presented in a VPS platform that allowed learners to order lab tests, diagnoses and treatments in a manner matching the scope and depth of actual practice. Clinical decisions made by the learners using open field entries within an EHR interface were analyzed and, after each decision, tailored clinical guidance (CG) was provided based on current evidence and expert recommendation. Learner decisions were collected post-CG and compared with each user9s baseline (pre-CG) data using a 2-tailed paired T-test to determine P values. The activity posted May 29, 2019; data were collected through October 15, 2019. Results: Significant improvements (reported as absolute) were observed after CG in clinical decisions made by oncologists: Conclusions: This study demonstrated that VPS that immerses and engages oncologists in an authentic and practical learning experience can significantly improve evidence-based clinical decisions related to diagnosis and management of patients with advanced EGFR-mutated NSCLC. Continued educational activities are needed to address the residual gaps in appropriate treatment and increase oncologists9 confidence in this clinical setting. Citation Format: Michelle A. Worst, Rich Caracio, Donna L. Topping, Suresh S. Ramalingam. Virtual patient simulation improves first-line treatment selection in advanced EGFR-mutated NSCLC [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2040.